Mesoblast First Half 2024 Earnings: EPS Beats Expectations, Revenues Lag
Mesoblast (ASX:MSB) First Half 2024 Results
Key Financial Results
Net loss: US$32.5m (loss narrowed by 21% from 1H 2023).
US$0.038 loss per share (improved from US$0.057 loss in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Mesoblast EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 8.0%. Earnings per share (EPS) exceeded analyst estimates by 6.8%.
Looking ahead, revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Biotechs industry in Australia.
Performance of the Australian Biotechs industry.
The company's shares are up 1.7% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Mesoblast has 1 warning sign we think you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
